Cargando…

Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study

BACKGROUND AND PURPOSE: New prophylactics for migraine, targeting calcitonin gene‐related peptide (CGRP), have recently emerged. Real‐world data are important for a comprehensive understanding of treatment response. We assessed the consistency of response to erenumab, a monoclonal CGRP receptor anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Vries Lentsch, Simone, Verhagen, Iris E., van den Hoek, Thomas C., MaassenVanDenBrink, Antoinette, Terwindt, Gisela M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Headache
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291504/ https://www.ncbi.nlm.nih.gov/pubmed/34424593 http://dx.doi.org/10.1111/ene.15075

Ejemplares similares

Serum CGRP in migraine patients using erenumab as preventive treatment
por: de Vries Lentsch, Simone, et al.
Publicado: (2022)

Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment
por: MaassenVanDenBrink, Antoinette, et al.
Publicado: (2018)

Clinic and genetic predictors in response to erenumab
por: Zecca, Chiara, et al.
Publicado: (2022)

Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other real‐world evidence
por: Khalil, Modar, et al.
Publicado: (2022)

Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies: A Prospective Follow-up Study
por: de Vries Lentsch, Simone, et al.
Publicado: (2022)

E-diary use in clinical headache practice: A prospective observational study
por: van Casteren, Daphne S, et al.
Publicado: (2021)

Sex differences in prevalence of migraine trigger factors: A cross-sectional study
por: van Casteren, Daphne S, et al.
Publicado: (2020)

Cold extremities in migraine: a marker for vascular dysfunction in women
por: Linstra, K. M., et al.
Publicado: (2020)

A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond
por: Garelja, Michael L., et al.
Publicado: (2022)

Behavioural intervention in medication overuse headache: A concealed double‐blind randomized controlled trial
por: Pijpers, Judith A., et al.
Publicado: (2022)

The potential danger of blocking CGRP for treating migraine in CADASIL patients
por: de Boer, Irene, et al.
Publicado: (2020)

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
por: Ashina, Messoud, et al.
Publicado: (2021)

Correction to: Clinical symptoms of androgen deficiency in men with migraine or cluster headache: a cross-sectional cohort study
por: Verhagen, Iris E., et al.
Publicado: (2021)

Clinical symptoms of androgen deficiency in men with migraine or cluster headache: a cross-sectional cohort study
por: Verhagen, Iris E., et al.
Publicado: (2021)

Validation of diagnostic ICHD-3 criteria for menstrual migraine
por: Verhagen, Iris E, et al.
Publicado: (2022)

European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update
por: Sacco, Simona, et al.
Publicado: (2022)

Comparing Perimenstrual and Nonperimenstrual Migraine Attacks Using an e-Diary
por: van Casteren, Daphne S., et al.
Publicado: (2021)

Jealousy in women with migraine: a cross-sectional case-control study
por: van Casteren, Daphne S., et al.
Publicado: (2020)

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
por: Simioni, Caio Vinicius de Meira Grava
Publicado: (2022)

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
por: Kubota, Gabriel Taricani
Publicado: (2022)

Improved Osteoarthritis during Erenumab Treatment for Migraine: A Case Report
por: Jantzen, Frederik Thal, et al.
Publicado: (2023)

Trigeminovascular calcitonin gene-related peptide function in Cacna1a R192Q-mutated knock-in mice
por: Chan, Kayi Y, et al.
Publicado: (2017)

Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system
por: Labastida-Ramírez, Alejandro, et al.
Publicado: (2020)

Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice
por: Mulder, Inge A., et al.
Publicado: (2020)

Revisiting dose-finding of monoclonal antibodies in migraine
por: Al-Hassany, Linda, et al.
Publicado: (2023)

Pain perception in women with menstrually-related migraine
por: Linstra, Katie M, et al.
Publicado: (2020)

Multinational descriptive analysis of the real‐world burden of headache using the Migraine Buddy application
por: Goadsby, Peter J., et al.
Publicado: (2021)

Effect of lockdown during COVID-19 on migraine: A longitudinal cohort study
por: Verhagen, Iris E, et al.
Publicado: (2021)

Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT study
por: Vernieri, Fabrizio, et al.
Publicado: (2022)

First‐line steroid treatment for spontaneous intracranial hypotension
por: Tonello, Simone, et al.
Publicado: (2022)

The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse
por: van Hoogstraten, Willem Sebastiaan, et al.
Publicado: (2019)

Headache medication and the COVID-19 pandemic
por: MaassenVanDenBrink, Antoinette, et al.
Publicado: (2020)

Basic Considerations for the Use of Monoclonal Antibodies in Migraine
por: Levin, Morris, et al.
Publicado: (2018)

Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study
por: MaassenVanDenBrink, Antoinette, et al.
Publicado: (2021)

Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
por: Christensen, Casper Emil, et al.
Publicado: (2018)

Could erectile dysfunction be a side effect of CGRP inhibition? A case report
por: Al-Hassany, Linda, et al.
Publicado: (2021)

Acute Migraine Therapy: New Drugs and New Approaches
por: Monteith, Teshamae S., et al.
Publicado: (2010)

Headache as an acute and post‐COVID‐19 symptom in COVID‐19 survivors: A meta‐analysis of the current literature
por: Fernández‐de‐las‐Peñas, César, et al.
Publicado: (2021)

Chronic migraine: Genetics or environment?
por: Chalmer, Mona Ameri, et al.
Publicado: (2021)

Headaches and obesity
por: Fortini, Ida, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mafkp4vo5e30ul3q1a4l9bh4d7